Rocket Lab's Growth Story Hits a Wall of Timing, Dilution and Delayed Ambition
Published on 08/25/2026 at 05:41 | Redaktion boerse-global.de
There's a peculiar disconnect playing out at Rocket Lab right now. The company is posting record revenue, stacking up new contracts, clearing regulatory hurdles for a multibillion-dollar acquisition — and its stock keeps sliding. The gap between operational momentum and market sentiment has become the story itself, overshadowing any single trading session.
The Numbers Say One Thing
The second quarter delivered a record $234 million in revenue, up 62 percent year over year. The backlog swelled to $2.36 billion, a 137 percent jump from a year earlier, and management has guided toward another record quarter with gross margins in the 29 to 31 percent range. Those are figures most space startups can only dream of.
August brought a flurry of operational wins: a successful Electron launch for Japan's Institute for Q-shu Pioneers of Space, selection for the US Space Force's NITE-STAR program, an eight-satellite deployment for MDA Space supporting Globalstar's direct-to-device services, and a partnership with Viasat on maneuverable security satellites. The 93rd Electron mission flew successfully, marking the 14th launch of the year — all with a perfect success rate.
Yet the share price tells a different tale. The stock has shed roughly 15 percent over the past week and sits 4.9 percent below its level at the start of the year. From the 52-week high of €133.80, the shares have retreated 56 percent. Even a headline-grabbing military contract announced three weeks ago failed to arrest the slide, with the stock down 11.2 percent since.
A Timeline That Keeps Slipping
The market's attention, however, has fixed on something else entirely: Neutron. Rocket Lab's heavy-lift rocket — the vehicle meant to carry the company beyond its small-launch niche into the more lucrative medium-payload market — has slipped again. Instead of launching this year, the company now aims merely to get Neutron to the pad by the fourth quarter of 2026, leaving the actual first flight window increasingly uncertain.
Should investors sell immediately? Or is it worth buying Rocket Lab?
For a stock whose valuation hinges substantially on Neutron's promise, every delay cuts deeper than it might for a secondary product. This is the bet that justifies much of the company's market premium, and the pattern is familiar to anyone who has watched young launch vehicle programs: SpaceX took longer than planned with Falcon 9, and others are still wrestling with their debut flights. Delays are the industry norm, not the exception.
Customers, at least, appear undeterred. Rocket Lab has signed a dedicated launch contract with Kepler Communications for Neutron from Wallops Island, Virginia — though not before 2028 at the earliest.
The Dilution Question Hangs Overhead
While operations hum along, the company's capital markets activity is drawing scrutiny. The antitrust waiting period for its acquisition of Iridium expired on August 12, clearing a major regulatory hurdle, and Rocket Lab has filed an S-4 registration with the SEC to issue shares as part of the purchase consideration. The transaction is clearly moving forward — and with it, the question of shareholder dilution becomes more concrete.
Adding to that picture, Rocket Lab has established a new agreement with Deutsche Bank Securities and Wells Fargo Securities permitting the sale of up to $1.944 billion in shares through an at-the-market program, though without expanding its existing framework. Combined with the equity component of the Iridium deal, the market appears to be weighing future dilution more heavily than current record results.
Insider activity reinforces that concern. Over the past twelve months, company insiders have sold shares worth $923.8 million with no offsetting purchases, according to media reports. CEO Peter Beck alone has executed 29 sell transactions covering more than 3.29 million shares in the last six months. While such selling is hardly unusual at growing companies, it complicates the narrative that the market alone is being overly pessimistic.
Not everyone is heading for the exits, though. ARK Invest used the mid-August weakness to add roughly 161,000 shares — a signal that long-term believers in the Electron, Neutron and Iridium story see opportunity where others see warning signs.
A Stock for the Risk-Tolerant
The current picture is one of a classic growth story overlaid with sector-wide skepticism, amplified by the repricing that followed SpaceX's public listing. The fundamentals argue for the company; the capital markets activity — the ATM program, the Iridium share swap — argues for continued near-term pressure.
With annualized volatility around 80 percent, this remains a stock for investors with genuine risk appetite. The central question for the coming months isn't whether Rocket Lab can grow — that much is settled. It's whether the market's patience can outlast a rocket program that keeps rewriting its own schedule, and whether operational strength can ultimately offset the cost of financial dilution.
Ad
Rocket Lab Stock: New Analysis - 25 August
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
